Connect with us

Health

Boswellia is a powerful anti-inflammatory herbal extract that can prevent cancer

Published

on

(Natural News) Ginger and turmeric might get all the attention when it comes to fighting cancer naturally, but there is one often-overlooked herb that can also help address this deadly disease: boswellia.

You might not have heard of boswellia, but you may know it by its other name: frankincense. It is said to be one of the gifts that was brought to Jesus when he was born, and it could prove to be an almost miraculous gift in the fight against cancer.

It comes from the resin of a tree called Boswellia serrata, which is native to Africa, Asia and the Middle East. It has long been used in traditional medicine for gastrointestinal relief and to ease ulcers and arthritis. Now, however, researchers are learning more about the unique way that it helps fight inflammation. In fact, it works far differently than conventional medications – and that’s a good thing given the many undesirable side effects caused by the current anti-inflammatory pharmaceuticals available.

What standard non-steroidal anti-inflammatory medications do is block the production of pro-inflammatory enzymes. The way they work, however, happens to block the production of an enzyme that is needed to keep the stomach lining healthy. This is why people who take NSAIDs often experience problems like stomach bleeding and irritation, kidney issues and peptic ulcers. Alternatives like Vioxx that skirt around this particular issue proved to be deadly and were withdrawn from the market.

Boswellia sets itself apart from these drugs by blocking a different pro-inflammatory enzyme known as 5-lipoxygenase (5-LOX). Not only does 5-LOX trigger the creation of pro-inflammatory leukotrienes, but it also contributes to diseases like cancer, asthma, atherosclerosis and arthritis. At the same time, boswellia stops the activity of HLE, or human leukocyte elastase, which has been linked to respiratory problems like chronic bronchitis, cystic fibrosis and emphysema. In fact, boswellia is currently the only substance known to man that can inhibit both 5-LOX and HLE.

Perhaps this is why a cell study that was published in the journal Molecular Pharmacology found that the extract of boswellia was more effective than standard chemotherapy drugs such as amsacrine, etoposide, and camptothecin when it came to stopping the enzymes that help cancer grow.

It has also been shown to fight the deadliest type of skin cancer, melanoma. It does this by interfering with melanoma cells’ ability to metastasize. In addition, a 2006 study showed that it can alter the expression of the tumor necrosis factor-alpha that can promote tumor cell growth and the spread of cancer.

Boswellia extract has also been shown in studies to help kill cells seen in brain cancer, prostate cancer, and leukemia. Meanwhile, a 2002 Cleveland Clinic study showed the extract is effective against the meningioma cells that form tumors in the brain’s covering.

Getting the benefits of boswellia

The benefits of boswellia aren’t limited to fighting cancer. It’s also an excellent remedy for rheumatoid arthritis and osteoarthritis thanks to its anti-inflammatory properties. It can also boost digestive system health, alleviating everything from diarrhea to inflammatory bowel diseases and ulcerative colitis. It can ward off liver problems like non-alcoholic fatty liver disease, and it even improves gum health.

If you’d like to get the benefits of boswellia for yourself, you can find it in cream, pill and resin formats. The different products have different percentages of boswellic acid and the dosages can vary quite a bit, so this is one time when it may be helpful to call upon an integrative healthcare provider or herbalist for advice.

It’s important to note, however, that you shouldn’t take boswellia if you are pregnant because it stimulates uterine blood flow and can cause miscarriages.

Continue Reading

Health

Hundreds of Indonesian healthcare workers contract COVID-19 despite vaccination, dozens hospitalised

Published

on

JAKARTA: More than 350 Indonesian doctors and healthcare workers have contracted COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, officials said, as concerns rise about the efficacy of some vaccines against more virulent virus strains.

Most of the doctors were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the Kudus district health office in Central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels.

Kudus is battling an outbreak believed to be driven by the more transmissible Delta variant which has pushed bed occupancy rates above 90 per cent in the district.

Designated as a priority group, Indonesian healthcare workers were among the first to be vaccinated when the inoculation drive started in January.

Almost all have received the COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac, according to the Indonesian Medical Association.

While the number of Indonesian healthcare workers dying from COVID-19 has decreased significantly – dropping from 158 deaths this January to 13 this May, according to data initiative group LaporCOVID-19 – public health experts say the Java hospitalisations are cause for concern.

“The data shows they have the Delta variant so it is no surprise that the breakthrough infection is higher than before because as we know the majority of healthcare workers in Indonesia got Sinovac, and we still don’t know yet how effective it is in the real world against the Delta variant,” said Dicky Budiman, an epidemiologist from Australia’s Griffith University.

Continue Reading

Health

China’s Covid-19 vaccine flops in Singapore too

Published

on

New Delhi: In a major setback to Chinas Covid vaccines, Singapore is not counting its citizens who received Sinovac Biotech shots as being vaccinated against Covid-19 due to lack of data to show that the doses are effective against coronavirus, especially the Delta strain.

“We don’t really have a medical or scientific basis or have the data now to establish how effective Sinovac is in terms of infection and severe illnesses on Delta,” local media cited health minister Ong Ye Kung as saying at a press conference on Wednesday.

The decision comes close on the heels of serious doubts arising over Chinese vaccines in Indonesia as those who have received the shots are also contracting Covid-19 and infections are surging in the country.

The Delta variant is currently the dominant strain of Covid-19 in Singapore and was identified in the city state in May. Only people who have received the Moderna and Pfizer shots, are being considered as vaccinated in the official records.

Singapore had allowed some private clinics to offer the Sinovac shot, CoronaVac, from mid-June. Around 17,000 people are reported to have received one dose of CoronaVac.

Local media had also reported Singapore’s director of medical services saying last month that evidence from other countries showed people who had taken CoronaVac were still getting infected.

Most of the vaccines being used by Indonesia have also come from China’s Sinovac Biotech. Some health workers inoculated with Sinovac jabs have been hospitalized due to Covid-19. A few have even died despite being fully immunized, according to a report in Nikkei Asia.

The Indonesian Doctors Association says that of the 14 doctors who died from the virus between February and May, ten had been fully vaccinated with Sinovac, while the rest had been given one dose.

Although there is a serious problem with Chinese vaccines due to inadequate data to show their efficacy, some countries are being forced to opt for them because of the cute shortage of vaccines worldwide amid the devastating pandemic.

Continue Reading

Health

102 people qualify for S$451,000 in Covid-19 vaccine injury financial aid to date: Ong Ye Kung

Published

on

SINGAPORE — The authorities have approved S$451,000 worth of financial aid to people who had suffered serious side effects from Covid-19 vaccines in Singapore, Health Minister Ong Ye Kung said on Tuesday (July 6).

The payments have either been paid out or are being processed to 102 applicants under the Vaccine Injury Financial Assistance Programme (Vifap) introduced by the Government in January.

They were among a total of 292 applicants who had submitted a complete Vifap application as of June 25, Mr Ong said.

Of these, 159 did not meet the eligibility criteria and 31 applications are waiting to be reviewed by an independent clinical panel or pending more medical information from the applicant’s doctor.

Mr Ong was responding in a written answer to a parliamentary question filed by Ms He Ting Ru, Member of Parliament for Sengkang Group Representation Constituency, who had asked about the applications made and payments approved under the programme.

TODAY has asked the Ministry of Health (MOH) for details of these approved payouts.

Vifap provides three tiers of support to people assessed to be adversely affected by their Covid-19 inoculation.

The first is a one-time payout of S$2,000 for patients who need hospitalisation and medical intervention and who later recover.

The second is a payout of up to S$10,000 that will be given to those who were hospitalised and required care in a high dependency or intensive care unit, but later recover from the side effects caused by the vaccine.



Continue Reading

Trending